Moving CAR-T Into Earlier Lines of Myeloma Treatment

By News Health
14 hours Ago

(MedPage Today) — Updated results from the CARTITUDE-1 trial showed that 33% of patients with heavily pretreated relapsed/refractory multiple myeloma who received ciltacabtagene autoleucel (cilta-cel; Carvykti) were alive and progression free…

Source link : https://www.medpagetoday.com/spotlight/asco-mm/116211

Author :

Publish date : 2025-06-24 13:40:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Enigmatic lizards somehow survived near Chicxulub asteroid impact

Millions of children at risk as vaccination uptake stalls

Physician Lawmaker Confronts RFK Jr. About ACIP Firings: 'You Lied'

Health Groups Cautiously Optimistic on Prior Authorization Announcement

Women's pelvises are shrinking – how is that changing childbirth?

Blood-Based KRAS Testing Fails in Ovarian Cancer